Dr. Fukuzawa obtained his PhD degree in 2007 from the Tokyo Institute of Technology in Japan where he discovered the physiological function of a novel GPCR, GPR116. In the same year he joined Chugai Pharmaceutical (Japan) to work on an SGLT2 inhibitor, tofogliflozin, for diabetes. In 2012 he moved to Singapore to work at Chugai Pharmabody Research, to focus on the anti-C5 antibody project, SKY59, as a project leader. More recently in 2017 he moved back to Japan to work again at Chugai Pharmaceutical where he is now involved in multiple antibody projects as a project leader for pharmacology function. Selected publications relevant for the current presentation:
SKY59, a novel recycling antibody, for complement-mediated diseases. Curr Med Chem. 2018 (in press), and
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017 Apr 24;7(1):1080.